Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-1.33 · Revenue $117.33M · 5 analysts
Est. EPS $-1.56 · Revenue $204.78M · 5 analysts
Est. EPS $-0.56 · Revenue $0.00 · 2 analysts
Est. EPS $-0.48 · Revenue $3.40M · 2 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-69.8M | -40.7% | -14.3% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-54.6M | -25.6% | +5.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.7% | -25.1% | -19.8% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 17.14x | -41.5% | -15.3% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $226.2M | -10.3% | -6.6% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.22 vs -1.30 | +6.3% | -0.32 vs -0.56 | +42.9% |
| Revenue Surprise | $0 vs $48.5M | -100.0% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | George Simeon | director, 10 percent owner: | Stock Option (right to buy) | A | 30,000 | $10.55 |
| Jun 9, 2026 | Schmid John P. | director | Stock Option (right to buy) | A | 30,000 | $10.55 |
| Jun 9, 2026 | LAPPE RODNEY W | director | Stock Option (right to buy) | A | 30,000 | $10.55 |
| Jun 9, 2026 | Gover Justin D. | director | Stock Option (right to buy) | A | 30,000 | $10.55 |
| Jun 9, 2026 | Shapiro David | director | Stock Option (right to buy) | A | 30,000 | $10.55 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Pratik Shah | Co-Founder, President, Chief Executive Officer, Principal Financial Officer & Executive Chairperson | USD 790,000 | Male | 1970 | Active |
Sean Jeffries | Chief Operating Officer | USD 698,000 | — | 1980 | Active |
Chris Storgard | Chief Medical Officer | USD 633,760 | — | 1966 | Active |
Julie D. Burgess | Chief Accounting Officer | — | Female | — | Active |
Aseem Z. Ansari | Co-Founder & Scientific Advisor | — | — | — | Active |
Doane Chilcoat | Chief Technology Officer | — | Male | — | Active |
Jim Kerr | Chief of Manufacturing & Product Development | — | Male | — | Active |
Tadimeti S. Rao | Chief Scientific Officer | — | — | — | Active |
Mustapha Parekh | General Counsel | — | Male | — | Active |
Chengzhi Zhang | Chief Chemist | — | — | — | Active |
An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech sitting on pivotal pipeline data have all landed on analysts' radars this week for very different reasons.
RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 Cash and securities of $207.4 million at quarter-end provide strong financial runway CARLSBAD, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported second quarter 2026 financial results and highlighted business updates and upcoming milestones across its GeneTAC® portfolio.
GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in its Phase 1 multiple-ascending dose (MAD) clinical trial evaluating DT-818 in adults with myotonic dystrophy type-1 (DM1).
Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to target repeat-expansion diseases. Their main value driver and drug candidate is DT-216P2 for FA. DSGN's trial on DT-216P2 is RESTORE-FA. This trial produced data that I believe makes DT-216P2 much more credible.
